Imugene Stock Quote IMU - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.049

Bid

0.049

Ask

0.05

Volume

10,660,723

0.049 Day's Range 0.0515

0.039 52 Week Range 0.15

Market Cap

358.671M

Previous Close

0.0485

Open

0.049

Last Trade

0.049

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

20,499,988

Shares Outstanding

7,319,810,809

Dividend Yield

PE Ratio

-2.45

Earnings Per Share (EPS)

-0.02

Revenue

4.97M

Net Profit

-149.68M

Sector

Biological Pds,ex Diagnstics

Industry

Biotechnology Animal & Plant

Website

www.imugene.com

Headquarters

Melbourne, Victoria, Aus

Founded

1986

Imugene Limited is listed in the Biological Pds,ex Diagnstics sector of the Australian Stock Exchange with ticker IMU. The last closing price for Imugene was AUD0.05. Over the last year, Imugene shares have traded in a share price range of AUD 0.039 to AUD 0.15.

Imugene currently has 7,319,810,809 shares outstanding. The market capitalization of Imugene is AUD355.01 million. Imugene has a price to earnings ratio (PE ratio) of -2.45.

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. TAMP is expected to enable localized, targeted delivery of CF33...

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or...

Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours

The Collaboration will evaluate Eureka’s anti-CD19 ARTEMIS® T-cell therapy in combination with Imugene’s CD19-expressing oncolytic virus onCARlytics in solid tumours Potential to address lack of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.001	2.08333333333	0.048	0.055	0.048	18053892	0.04991198	DE
4	-0.003	-5.76923076923	0.052	0.055	0.047	16666646	0.0494527	DE
12	-0.006	-10.9090909091	0.055	0.081	0.047	20499988	0.05531188	DE
26	-0.034	-40.9638554217	0.083	0.0885	0.047	21292358	0.0611308	DE
52	0.004	8.88888888889	0.045	0.15	0.039	28412328	0.082324	DE
156	-0.381	-88.6046511628	0.43	0.625	0.039	23223964	0.16024313	DE
260	0.028	133.333333333	0.021	0.625	0.016	22266505	0.15752591	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WNXWellnex Life Ltd	AUD 0.75 (4,066.67%)	47.87k
BSAOBSA Ltd	AUD 0.265 (120.83%)	82.76k
DOUDouugh Limited	AUD 0.009 (100.00%)	17.97M
GMNGold Mountain Limited	AUD 0.002 (100.00%)	603.58k
ATVRTradeable Rights Oct 2024	AUD 0.002 (100.00%)	8.31M
CPOOCulpeo Minerals Ltd	AUD 0.001 (-66.67%)	389.46k
ADNOCAndromeda Metals Limited	AUD 0.001 (-66.67%)	10.5M
MHCManhattan Corporation Limited	AUD 0.001 (-50.00%)	7.8M
TMSOTennant Minerals Ltd	AUD 0.001 (-50.00%)	1.04M
TVNOTivan Ltd	AUD 0.007 (-36.36%)	2.92k
OVTOvanti Ltd	AUD 0.026 (73.33%)	173.06M
ERAEnergy Resources Of Australia Limited	AUD 0.006 (-33.33%)	67.1M
LKELake Resources N L	AUD 0.079 (12.86%)	53.78M
OAROAR Resources Limited	AUD 0.002 (0.00%)	50.2M
AVEAvecho Biotechnology Limited	AUD 0.002 (0.00%)	47.79M